Clinical Trial Update: Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, and efficacy signals of NNC 0070-0002-0182 in overweight or obese volunteers; the study was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• NNC 0070-0002-0182

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Metabolism and Nutrition Disorder, Obesity | Phase 1 | Status: TERMINATED